The International Association for the Study of Lung Cancer (IASLC) is set to host the 2024 World Conference on Lung Cancer (WCLC) from September 7-10 in San Diego, California. Dr. Eric Singhi, a thoracic oncologist at MD Anderson Cancer Center, recently shared with international media the key studies he is most eager to follow at the 2024 WCLC.

“In the field of early-stage resectable non-small cell lung cancer (NSCLC), we’ve seen significant advancements in perioperative treatments over the past few years, especially with the introduction of immune checkpoint inhibitors. The first Presidential Symposium, scheduled for September 8, will feature two important presentations comparing perioperative immunotherapy with neoadjuvant immunotherapy strategies in resectable NSCLC patients. Dr. Patrick Forde will present a patient-level data analysis from the CheckMate 77T and CheckMate 816 trials, addressing a critical clinical question: How should we choose between adjuvant, neoadjuvant, and perioperative treatment approaches for resectable NSCLC?” Dr. Singhi said. “I am very much looking forward to this analysis, as it could provide valuable insights for decision-making in the treatment of resectable NSCLC.”

Abstract Number: PL02.08

Title: Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC: Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816

Presenter: P.M. Forde | Bloomberg-Kimmel Institute for Cancer Immunotherapy

Dr. Tina Cascone will also present results from the NeoCOAST-2 trial, another highlight of the Presidential Symposium at WCLC 2024. “The NeoCOAST-2 trial is exploring a crucial question: Beyond traditional PD-(L)1 inhibitors, how can we safely and effectively treat early-stage resectable NSCLC patients? The potential to introduce novel immunotherapy agents in this setting is particularly exciting,” Dr. Singhi noted.

Abstract Number: PL02.07

Title: Neocoast-2: Efficacy and Safety of Neoadjuvant Durvalumab (D) + Novel Anticancer Agents + CT and Adjuvant D ± Novel Agents in Resectable NSCLC

Presenter: T. Cascone | MD Anderson Cancer Center

The 2024 WCLC will also showcase pivotal data in metastatic lung cancer. Dr. Cai-Zhuo Zhou will present the primary analysis of the HARMONi-2 trial. “We’ve already heard from press releases that Ivonescimab has shown significant progression-free survival (PFS) benefits across all subgroups, and I am very eager to see the detailed data,” Dr. Singhi said. “Ivonescimab appears to be the first drug in a phase III trial to demonstrate clinically meaningful benefits over Pembrolizumab in the treatment of metastatic NSCLC.”

Abstract Number: PL02.04

Title: Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: Primary Analysis of HARMONi-2

Presenter: Caicun Zhou | Tongji University Shanghai East Hospital

“I am also very excited to hear the latest updates on HER2-positive metastatic NSCLC and the progress in HER2-targeted therapies from the second Presidential Symposium, scheduled for September 9 at 8:30 AM,” Dr. Singhi added. This session will cover several updates on HER2-targeted therapies in lung cancer, including the phase I/II SOHO-01 study, which assesses the safety and efficacy of BAY 2927088 in patients with HER2-mutant NSCLC. Another notable study is the Beamion LUNG-1 trial, which will present phase Ib data on Zongertinib for HER2 mutation-positive NSCLC, involving a patient cohort similar to that in the SOHO-01 study.

Abstract Number: PL04.03

Title: Safety and Efficacy of BAY 2927088 In Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study

Presenter: X. Le | MD Anderson Cancer Center

Abstract Number: PL04.04

Title: Primary Phase Ib Analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in Patients with HER2 Mutation-Positive NSCLC

Presenter: G. Ruiter | Netherlands Cancer Institute, Department of Clinical Pharmacology